Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients
Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with…